Bayer and Regeneron Pharmaceuticals announced positive Phase III results for the first of two studies of VEGF Trap-Eye (aflibercept ophthalmic solution) for patients with macular edema due to central retinal vein occlusion. Regeneron get a $10 million milestone payment from Bayer because the trial met its primary endpoint. Release